dr. tagawa on abiraterone and docetaxel in mcrpc
Published 10 years ago • 534 plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
1:10
dr. oh on the use of abiraterone and docetaxel in mcrpc
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
5:59
apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mcrpc
-
1:32
dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:49
dr. tagawa on preliminary data with 225ac-j591 in mcrpc
-
1:05
dr. agarwal on candidates for docetaxel versus abiraterone and prednisone
-
1:24
dr. posadas on a phase ib study of abiraterone plus docetaxel for mcrpc
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
1:51
dr. tagawa on remaining questions with psma-targeted radionuclide therapy in mcrpc
-
0:20
copy of dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
1:54
dr. hahn on patient selection for abiraterone versus docetaxel in mhspc
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
1:32
dr. tagawa on next steps for taxanes in prostate cancer
-
0:54
convincing long-term survival with abiraterone in mcrpc
-
1:19
comparing abiraterone and docetaxel in prostate cancer treatment
-
1:26
dr. oh discusses choosing abiraterone in prostate cancer
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer